Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Pharmacokinetics of VV116 in Healthy Volunteers
NCT05221138Phase 1Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Dec 2021
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deuremidevir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Vigonvita Life Sciences. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to last measurable concentration and 2 more. Started Dec 2021; status: completed.
02
Drugs
deuremidevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05221138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05221138.